Provided by Tiger Trade Technology Pte. Ltd.

Cogent Biosciences, Inc.

34.18
-1.1000-3.12%
Pre-market: 34.260.0800+0.23%07:40 EDT
Volume:1.59M
Turnover:54.85M
Market Cap:5.93B
PE:-15.82
High:35.57
Open:35.09
Low:34.08
Close:35.28
52wk High:43.73
52wk Low:11.60
Shares:173.52M
Float Shares:166.83M
Volume Ratio:1.14
T/O Rate:0.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1600
EPS(LYR):-2.5504
ROE:-109.74%
ROA:-43.84%
PB:12.68
PE(LYR):-13.40

Loading ...

Compass Pathways targets late 2027 approval for treatment-resistant depression psychedelic therapy

Reuters
·
Jun 05

Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT)

TIPRANKS
·
Jun 01

Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL), Cogent Biosciences (COGT) and Anteris Technologies Global Corp. (AVR)

TIPRANKS
·
Jun 01

Cogent Biosciences announces data from analysis of PEAK Phase 3 trial

TIPRANKS
·
Jun 01

BRIEF-Cogent Biosciences Announces Detailed Clinical Data From Peak Phase 3 Trial With Bezuclastinib In Combination With Sunitinib

Reuters
·
May 30

Cogent says PEAK Phase 3 trial shows bezuclastinib-sunitinib combo extends PFS in second-line GIST

Reuters
·
May 30

Cogent Biosciences - Bezuclastinib Combination Demonstrates Statistically Significant Pfs Advantage in Gist Patients

THOMSON REUTERS
·
May 30

Cogent Biosciences Announces Detailed Clinical Data From Peak Phase 3 Trial With Bezuclastinib in Combination With Sunitinib in Gastrointestinal Stromal Tumors (Gist) at 2026 American Society of Clinical Oncology (Asco) Annual Meeting

THOMSON REUTERS
·
May 30

BUZZ-U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's

Reuters
·
May 29

Cogent Biosciences announces FDA acceptance of bezuclastinib NDA

TIPRANKS
·
May 28

BUZZ-Cogent rises as US FDA accepts marketing application for cancer drug

Reuters
·
May 28

Cogent says FDA accepts bezuclastinib-sunitinib NDA for GIST, grants priority review

Reuters
·
May 28

Cogent Biosciences - FDA Does Not Plan Advisory Committee or Identify Review Issues for Nda

THOMSON REUTERS
·
May 28

Cogent Biosciences - FDA Grants Priority Review to Nda With Pdufa Date November 30, 2026

THOMSON REUTERS
·
May 28

Cogent Biosciences Announces FDA Acceptance of New Drug Application (Nda) With Priority Review for Bezuclastinib in Combination With Sunitinib for Patients With Gist

THOMSON REUTERS
·
May 28

Cogent Biosciences to present at Jefferies Global Healthcare Conference

Reuters
·
May 27

Cogent Biosciences (COGT) Receives a Rating Update from a Top Analyst

TIPRANKS
·
May 10

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT)

TIPRANKS
·
May 06

Guggenheim Sticks to Their Buy Rating for Cogent Biosciences (COGT)

TIPRANKS
·
May 06

Analysts Offer Insights on Healthcare Companies: Orthofix Medical (OFIX), BioNTech SE (BNTX) and Cogent Biosciences (COGT)

TIPRANKS
·
May 06